Madrigal Pharmaceuticals Email Format
Pharmaceutical Manufacturing
・
501-1,000 employees
・
Conshohocken, PA, USA
Madrigal Pharmaceuticals is a biopharmaceutical company developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@madrigalpharma.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
2016
Headquarters
Conshohocken, PA, USA
Revenue
$100M-$250M
FUNDING Stage
Public
Website
Key Executives
Bill Sibold (President and Chief Executive Officer), Mardi C. Dier (Executive Vice President, Chief Financial Officer), Mark Underwood (Executive Vice President, Business Planning & Operations)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals uses the firstinitiallast format, so Jane Smith would be jsmith@madrigalpharma.com.
What disease area does Madrigal Pharmaceuticals focus on?
Madrigal Pharmaceuticals is focused exclusively on metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease. Its approved therapy Rezdiffra (resmetirom) was the first and only FDA-approved treatment for MASH with moderate to advanced liver fibrosis.
How many patients were being treated with Rezdiffra from Madrigal Pharmaceuticals as of 2026?
By the end of the first quarter of 2026, more than 42,250 patients were actively being treated with Rezdiffra, with Madrigal Pharmaceuticals reporting net revenues of $311.3 million for that quarter alone, a 127% increase year over year.
Where is Madrigal Pharmaceuticals headquartered and how large is the company?
Madrigal Pharmaceuticals is headquartered in Conshohocken, PA, and employs approximately 1,074 people. Tools like Clay can help you find and verify the right contact at Madrigal for outreach or prospecting purposes.
Does Madrigal Pharmaceuticals have regulatory approval for Rezdiffra outside the United States?
Yes. Madrigal Pharmaceuticals received European Commission approval for Rezdiffra in August 2025, making it the first approved MASH therapy in the EU, with commercial launches rolling out on a country-by-country basis starting with Germany.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating